Short answer
Relay Therapeutics, Inc. (RLAY) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). ATM equity program expanded from $250M to $462.98M, enabling up to $212.98M of additional stock sales.
Relay Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- ATM equity program expanded from $250M to $462.98M, enabling up to $212.98M of additional stock sales
- Approximately $162.98M already sold under the agreement, indicating substantial prior equity financing
- Potential dilution and share-price pressure from future issuance, though sales remain discretionary
- TD Cowen compensation capped at 3.0% of gross proceeds, reducing net cash raised
- Proceeds provide Relay Therapeutics additional financing flexibility without mandatory borrowing or fixed repayment terms
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.2 with detailed financial results
Item EX-99.1 · Exhibit EX-99.1
- ATM equity-sales authorization increased from $250 million to $462,978,049, expanding potential financing capacity
- Additional share issuance creates dilution risk for existing shareholders and possible financing for operations or pipeline development
- Sales permitted through Nasdaq, block trades, negotiated transactions, or other lawful at-the-market methods
- Amendment adds outbound-investment compliance representations and updates counsel, address, and General Counsel information
- Prospectus supplement required within two business days, potentially enabling near-term equity sales visibility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Relay Therapeutics, Inc. 8-K filings
Get the next RLAY 8-K as it lands
Follow RLAY for push alerts, or ask the research agent what this filing means.